rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5), administered every 21 days for 4 cycles, followed with or without gefitinib (250 mg/day) for 6 months.
|
24585406 |
2014 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Exon 19 deletions and exon 21 L858R substitutions are the most common mutations, accounting for approximately 90% mutations in NSCLC; these are termed classic mutations and result in high sensitivity to tyrosine kinase inhibitors (TKIs).
|
31367543 |
2019 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib.
|
15492241 |
2004 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we show that L858R and deletion mutant EGFR proteins found in NSCLC interact with the chaperone and are sensitive to degradation following Hsp90 inhibition.
|
16024644 |
2005 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the L858R mutation in exon 21, is rare, and only few data exist on this patient population.
|
26124334 |
2015 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions.
|
25990507 |
2015 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.
|
28789464 |
2017 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R.
|
31571928 |
2019 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions.
|
28958502 |
2017 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Plasma samples derived from 22 patients with stage IIIB/IV NSCLC harboring EGFR mutations in matched tumor tissues confirmed by amplification refractory mutation system (ARMS) analysis were subjected to two multiplex ddPCR panels to assess the abundance of tyrosine kinase inhibitor (TKI) ‑sensitive (19DEL, L858R) and TKI‑resistant (T790 M) mutations.
|
29067441 |
2017 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We were able to identify EGFR mutations in NSCLC tumor samples immunohistochemically with a sensitivity of 79% using the anti-delE746-A750 antibody and 83% using the anti-L858R antibody.
|
20423982 |
2010 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We were able to identify EGFR mutations in NSCLC effusion and CSF with a sensitivity of 100% (5/5) using the anti-delE746-A750 antibody and 100% (8/8) using the anti-L858R antibody.
|
21444121 |
2011 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Together, exon 19 deletion and exon 21 L858R gene substitution are present in about 10% of Caucasian patients and 20-40% of Asian patients with non-small cell lung cancer.
|
25855240 |
2016 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting.
|
30336693 |
2018 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for monitoring treatment response to EGFR TKIs and also predict drug resistance.Clinically relevant mutations including exon 19 deletion (ex19del), L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI.
|
26755650 |
2016 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor <i>(EGFR)</i> mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine kinase inhibitors (TKIs).
|
29340050 |
2017 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation).
|
29737372 |
2018 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC).
|
24353160 |
2013 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Adult patients with stage IIIB/IV EGFR Mut+ NSCLC (exon 19 deletion or exon 21 L858R mutation) who had received first-line systemic therapy between 2011 and 2016 were included.
|
30608948 |
2019 |